- Home
- SNCR vs ABOS Comparison
SNCR vs ABOS Comparison
Compare SNCR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- ABOS
- Stock Information
- Founded
- SNCR 2000
- ABOS 1996
- Country
- SNCR United States
- ABOS United States
- Employees
- SNCR N/A
- ABOS N/A
- Industry
- SNCR EDP Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SNCR Technology
- ABOS Health Care
- Exchange
- SNCR Nasdaq
- ABOS Nasdaq
- Market Cap
- SNCR 101.2M
- ABOS 83.5M
- IPO Year
- SNCR 2006
- ABOS 2021
- Fundamental
- Price
- SNCR $9.61
- ABOS $1.39
- Analyst Decision
- SNCR Strong Buy
- ABOS Strong Buy
- Analyst Count
- SNCR 1
- ABOS 3
- Target Price
- SNCR $13.00
- ABOS $9.33
- AVG Volume (30 Days)
- SNCR 35.4K
- ABOS 232.9K
- Earning Date
- SNCR 03-11-2025
- ABOS 03-25-2025
- Dividend Yield
- SNCR N/A
- ABOS N/A
- EPS Growth
- SNCR N/A
- ABOS N/A
- EPS
- SNCR N/A
- ABOS N/A
- Revenue
- SNCR $170,789,000.00
- ABOS N/A
- Revenue This Year
- SNCR $7.56
- ABOS N/A
- Revenue Next Year
- SNCR $4.58
- ABOS N/A
- P/E Ratio
- SNCR N/A
- ABOS N/A
- Revenue Growth
- SNCR 61.81
- ABOS N/A
- 52 Week Low
- SNCR $6.02
- ABOS $1.28
- 52 Week High
- SNCR $15.46
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- SNCR 47.09
- ABOS 37.15
- Support Level
- SNCR $9.58
- ABOS $1.36
- Resistance Level
- SNCR $10.52
- ABOS $1.52
- Average True Range (ATR)
- SNCR 0.60
- ABOS 0.08
- MACD
- SNCR -0.07
- ABOS 0.01
- Stochastic Oscillator
- SNCR 31.22
- ABOS 40.30
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a leading provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and highly scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.